View Xevant’s recent media coverage from around the web


People Spent the Most Money on These 25 Prescription Drugs Last Year

U.S. spending on prescription drugs amassed $722 billion in 2023, a nearly 14% uptick from 2022, marking the largest increase in spending in 20 years, according to a new study. The diabetes and weight loss medication semaglutide (Ozempic, Wegovy, and Rybelsus) topped the list. While drug prices did rise, the data and experts point to other, more significant factors for the national increase in spending.

Read More

Podcast: Understanding the politics of drug pricing in the United States

Everyone says they want more affordable drugs for patients that need them, but people disagree quite a bit on who’s to blame for the current status quo of sky-high prescription prices – not to mention how they might be corrected.
To help unpack some of those trends and conflicting perspectives, Brandon Newman, CEO of healthcare analytics firm Xevant, joins host Jonah Comstock on today’s episode of the pharmaphorum podcast. They discuss the oft-maligned role of pharmacy benefit managers, problems with the drug pricing provisions in the Inflation Reduction Act, the lack of (and importance of) price transparency, the various levers available to the government to address prices, and what companies like Xevant are doing right now to lower drug prices for patients.

Read More

Xevant’s Powerful PBM Tools for Improved Cost Management & Transparency

Access to critical pharmaceuticals at the lowest net cost for patients remains an essential objective that drives the American healthcare system. PBMs play a significant role in this equation, negotiating with manufacturers and navigating the complexities of drug pricing to achieve the best possible offers. However, the market’s dynamic character, combined with developing rebate structures, requires some deviation from typical data management and reporting approaches. Xevant, a revolutionary pharmaceutical analytics platform, addresses this issue, providing a full suite of must-have analytics solutions that equip PBMs with the tools they need to achieve maximum cost reductions and transparency for their clients.

Read More

Commentary from Xevant CEO Brandon Newman: Another view of Biden’s prescription drug cost initiative

In his most recent State of the Union speech, President Joe Biden presented a detailed plan to combat the rising costs of prescription drugs, a major issue that affects millions of people in the U.S. Among the measures that Biden proposes is the limitation of out-of-pocket costs for prescription drugs while simultaneously allowing the federal government the right to negotiate drug pricing. This represents a considerable shift from the regulations that have been in place previously surrounding healthcare. Given my position as the CEO of Xevant, I offer my perspective on these developments.

Read More

Xevant: Empowering America to Achieve the Lowest Net-Cost Drugs for a Healthier Future

Healthcare expenses have surged to unprecedented levels, a trend highlighted by the fact that over 900 prescription medications experienced price hikes in January alone. This occurs as legislative entities grapple with the intricate details of formulating effective drug pricing policies. Amid these challenges, there are emerging signs of innovative solutions making a difference. One notable example is Xevant, a platform specializing in pharmaceutical analytics, which stands as a beacon of how technology and forward-thinking can contribute to making healthcare more accessible and affordable for the American population. Xevant is not merely participating in discussions about securing cost-effective medications; it is at the forefront of this movement.

Read More

Xevant: Revolutionizing the Path to Affordable Prescription Drugs in America

Healthcare costs are record-high, evidenced by the fact that over 900 prescription drugs saw price increases in January alone. Meanwhile, legislative bodies are struggling to address the complexities of drug pricing legislation. Amid these challenges, innovation is starting to show promising signs. Xevant, a pharmaceutical analytics platform, is a testament to what technology and vision can achieve in pursuit of making healthcare more affordable for all Americans. With its sophisticated platform, Xevant is not just part of the conversation about achieving the lowest net-cost drugs; it is leading the charge.

Read More

High Costs of GLP-1 Drugs Fuel Debate

The development of glucagon-like peptide 1 receptor agonist drugs for the treatment of diabetes and obesity has sparked another debate around the cost of healthcare in the U.S. Studies show that these drugs effectively aid weight loss in patients with type 2 diabetes and obesity, but their U.S. price tags are a deterrent to many patients.

Read More

The Future Of Drugstore Retailing

After a recent conversation with Brandon Newman, CEO of XEVANT, I am convinced that there are many ways for drugstores to save at a time when competition is very intense, and operations are very costly.

Brandon, who spoke at PBMI (Pharmacy Benefit Management Institute), pointed to the underlying factors contributing to drugstore closures. They include operating costs that have increased greatly, forcing chains to close many lower-volume stores. We see that problem confronting many industries. However, in the pharmacy/drugstore industry, he also pointed out some unique industry challenges. He noted that drugstore companies may have difficulties securing the best/lowest drug prices since some government regulations require compliance.

Read More

Why Your Drugstore Is Closing

Among the reasons for store closures are rising drug prices, lower staff enrollment, and historic opioid lawsuits, which have impacted each company’s financial standing. Brandon Newman, CEO of data analysis company Xevant, told Newsweek: “First and foremost, rising drug costs are a central concern. As prices escalate, both pharmacies and patients are increasingly burdened. This not only affects pharmacies’ ability to manage inventory efficiently but also places a significant financial strain on patients. The impact on the business health of pharmacies is undeniable.”

Read More

The Impacts of March-In Rights on Healthcare and Drug Pricing

On December 7th, President Joe Biden’s administration proposed the potential use of march-in rights under the Bayh-Dole Act. This marks a pivotal moment in the landscape of drug pricing and healthcare. Xevant, a leader in healthcare analytics, is at the forefront of finding the equilibrium between making drugs affordable and fostering the continuous innovation crucial […]
Read More

Ready to get started?